ArticleAmerican journal of translational research2025
Application of circulating tumor DNA methylation characteristics in early diagnosis and prognosis monitoring of lung cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of immune and ferroptosis-related gene cysteine dioxygenase type 1 (CDO1) as a prognostic biomarker in colorectal cancer, relating to immunotherapy response distinction.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the value of circulating tumor DNA (ctDNA) methylation for early detection and prognostic monitoring of lung cancer.
methodsA retrospective analysis was conducted on the DNA methylation test results of 150 lung cancer patients and 100 patients with benign lung lesions enrolled from January 2021 to December 2023. Quantitative methylation fluorescence analysis and bisulfite sequencing were used to measure ctDNA gene methylation, with ROC curves assessing early-stage diagnostic value. Lung cancer patients were followed for 1 year, then grouped by survival status. Cox regression identified poor prognosis factors, and ROC curves evaluated ctDNA methylation's prognostic value. An external cohort of 80 lung cancer patients from May 2022 to December 2023 validated the model using ROC and calibration curves.
resultsThe positivity rates of SHOX2, CDO1, and SOX17 were significantly higher in lung cancer patients than those in controls (all
conclusionsAbnormal methylation of SHOX2, CDO1, and SOX17 is prevalent in lung cancer, potentially serving as biomarkers for early diagnosis and prognostic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.